Ritalin Fraud
The law firm of Waters &
Kraus takes this opportunity to announce the filing in Texas of a class action lawsuit
entitled Hernandez, Plaintiff, Individually and on Behalf of all Others Similarly
Situated v. Ciba Geigy Corporation, U.S.A., Novartis Pharmaceuticals Corporation, Children
and Adults With Attention-Deficit/Hyperactivity Disorder (CHADD), and the American
Psychiatric Association. Dr. Peter Breggin is serving as a medical consultant in the
case. While this filing is a departure from Waters & Kraus continuing practice of
toxic exposure and cancer cases, the pattern and practice of improper conduct on the part
of the defendants in this case rivals that of the asbestos corporate defendants and
tobacco companies in other cases. The suit states allegations based on fraud and conspiracy. From approximately 1955
through 1995, the exclusive or primary manufacturer and supplier of Ritalin in this
country was defendant Ciba-Geigy Corp., U.S.A. ("Ciba"). In 1996 Ciba merged
with Sandoz Pharmaceuticals Corp. to become defendant Novartis Pharmaceuticals Corp.
("Novartis"). Ciba/Novartis has manufactured, marketed and sold Ritalin since
approximately 1955. Ciba/Novartis planned, conspired, and colluded to create, develop and promote the
diagnosis of Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder
(ADHD) in a highly successful effort to increase the market for its product Ritalin. In
addition to its actions and involvement with the creation of the ADD and ADHD diagnosis,
Ciba/Novartis took steps to promote and dramatically increase the sales of Ritalin by way
of the following: Defendant CHADD (Children and Adults with Attention Deficit/Hyperactivity Disorder) has
been a recipient of financial donations and contributions from Defendants Ciba/Novartis
for many years. CHADD received $748,000 from Ciba/Novartis in the period 1991 to 1994
alone. During the periods when CHADD received funding from Ciba/Novartis, CHADD
deliberately made efforts to increase the sales of Ritalin, and to increase the supply of
methylphenidate (the generic name for Ritalin) available in the United States, and to
reduce or eliminate laws and restrictions concerning the use of Ritalin and
methylphenidate in the United States, all to the financial benefit of Ciba/Novartis.
Ciba/Novartis made such financial contributions with the purpose of advertising and
promoting sales of Ritalin an internationally controlled substance. Ciba/Novartis
has thus repeatedly violated Article 10 of the United Nations Convention on Psychotropic
Substances, 1019 U.N.T.S. 175 (1971). CHADDs activities nationwide have led to significant increase in the amount of
Ritalin taken by school children and have directly resulted in enormous profits to
Ciba/Novartis. Parents, the school districts and other interested parties are generally unaware that
use of Ritalin can cause a significant number of health problems and risks, including but
not limited to the following:
Cardiovascular
Central Nervous System
Gastrointestinal
Endocrine/Metabolic
Other
Withdrawal and Rebound